



# asia pacific



Australia, China, India, Indonesia, Japan,  
New Zealand, South Korea, Taiwan

value of insight

a consulting & publishing company

*pharmahandbook*®  
A Guide to the International Pharmaceutical Industry  
2013 – Asia-Pacific Report

**Author:** Todd D. Clark

**Research:** Shannon Torley

**Sales & Marketing:** D. Scott Clark

**Value of Insight Consulting, Inc.**

2522 Center Avenue

Fort Lauderdale, Florida 33308

Phone: (US) 954 302 8852

Fax: (US) 954 252 3927

[www.voiconsulting.com](http://www.voiconsulting.com)

[publications@voiconsulting.com](mailto:publications@voiconsulting.com)

Copyright 2013 Value of Insight Consulting, Inc.

All rights reserved. See user license agreement at end of document for details.

To learn more about VOI Consulting's pharmaceutical publishing and advisory services, contact us at (US) 954 302 8852 or visit our website at [www.voiconsulting.com](http://www.voiconsulting.com).

## About the Author



Todd Clark is the President of Value of Insight (VOI) Consulting, Inc. and the author of both *PharmaHandbook — A Guide to the International Pharmaceutical Industry*, the first-ever single source reference guide on the pharmaceutical business and regulatory environments in 39 countries, and *GenericHandbook —*

*A Guide to the US Generic Pharmaceutical Industry*, a comprehensive reference guide to the marketing, intellectual property, legal, regulatory and competitive aspects of the generic drug sector in the United States. The publications have been purchased by customers in more than 45 countries and have received highly favorable reviews from business and academic press.

Since founding VOI Consulting in 1998, Todd has shared his expertise with 11 of the top 15 branded drug companies, as well as leading generic manufacturers, biotech firms, investment banks and cutting-edge health technology services — advising them on global strategies regarding market entry, clinical trial design, intellectual property issues, regulatory compliance, marketing strategy, competitive intelligence, pricing, reimbursement, allocation of sales-force resources and more. He is a member of the pharmaceutical advisory team for the Gerson Lehman Group, has served as an expert witness in pharmaceutical industry litigation, and is frequently quoted in trade publications.

In addition to his work with VOI, Todd is an adjunct business professor, teaching courses in marketing, business strategy and managerial decision making, at Tulane University, Loyola University the University of Phoenix Online. He developed a healthcare management curriculum for Tulane and taught healthcare policy, payment and regulation within that program. He also served on the Business Studies Advisory Committee for Tulane.

Todd is a graduate of Tulane University and has an MBA from the Kellogg School of Management at Northwestern University where he majored in strategy, finance, and marketing.

## About VOI Consulting, Inc.



Founded in 1998, Value of Insight Consulting, Inc. (VOI) is a pharmaceutical consulting and publishing company dedicated to

providing pharmaceutical and biopharmaceutical clients with fact-based analysis and business intelligence to meet market challenges in today's highly competitive global environment. Employing innovative research techniques and advanced analytical tools, our services help clients minimize risks, cut costs and maximize commercial opportunities.

VOI stands for Value of Insight and plays on the statistical term "Value of Information," which describes the difference between expected outcomes in the absence of information and expected outcomes in the presence of information derived through applied research techniques, sound analysis and experienced judgment. For our clients — who have included 19 of the top 25 pharmaceutical companies — this insight translates into measurable success.

VOI Consulting's reputation as a leading publisher of pharmaceutical industry reference books and in-depth pharmaceutical market research reports has distinguished the company as a trusted source of research and analysis.

Our services are global in reach, are relevant for any therapeutic category and span the entire range of the pharmaceutical lifecycle. Whether you are planning a clinical trial or need to assess the market for a generic drug, whether you operate in developed countries or are looking at emerging opportunities in countries like China, India, Russia, Turkey or Latin America, VOI Consulting can help you execute more effectively.

## Contact Information

Email: [toddclark@voiconsulting.com](mailto:toddclark@voiconsulting.com)

Website: [www.voiconsulting.com](http://www.voiconsulting.com)

## Table of Contents

<b>Copyright .....</b>	<b>1</b>
<b>About the Author .....</b>	<b>2</b>
<b>About VOI Consulting, Inc. ....</b>	<b>2</b>
<b>Contact Information .....</b>	<b>2</b>
<b>Notes on Methodology .....</b>	<b>15</b>
Overview .....	16
Calculation of GDP and National Healthcare Spending .....	16
Market Calculations .....	16
Time Considerations .....	16
Monetary Figures, Exchange Rates & Growth Calculations .....	16
Legal Notes .....	17
<b>Country: Australia .....</b>	<b>20</b>
Healthcare System .....	22
Pharmaceutical Market .....	24
Market Profile .....	25
Market Structure .....	25
The Pharmaceutical Benefits Scheme .....	26
Section 100 Programs .....	28
Memorandum of Understanding .....	29
Forecasts .....	29
Regulatory .....	30
Approval Procedures .....	31
TGA/Medsafe Merger (ANZTPA) Status .....	31

Pricing.....	32
Cost Recovery.....	35
Formulary Categories.....	36
Managed Entry Scheme (MES).....	36
Mandatory Price Reductions.....	37
Price Disclosure.....	37
Payment.....	38
Generics.....	38
Generic Substitution.....	38
The Generic Market.....	39
R&D / Clinical Trials.....	39
Overview.....	39
Regulatory / Approval.....	40
Manufacturing.....	41
Distribution.....	43
Trade.....	45
AUSFTA.....	45
Patent & Intellectual Property Issues.....	45
Marketing.....	47
Marketing Regulations.....	47
<b>Country: China .....</b>	<b>52</b>
Healthcare System.....	54
Health Reforms.....	57
Pharmaceutical Market.....	59
Market Profile and Structure.....	60
Product Segments.....	63
Market Access.....	64
Market Fragmentation.....	65

Impact of 2009-2011 Health Reforms .....	66
Market Performance and Forecasts.....	66
Regulatory.....	67
<a href="http://eng.sfda.gov.cn/WS03/CL0767/61640.html">http://eng.sfda.gov.cn/WS03/CL0767/61640.html</a> .....	68
Approval Procedures.....	68
Provisional vs. Final Standards.....	70
Pricing.....	70
Payment.....	72
NRDL.....	72
EDL.....	73
Hospitals and Tendering Systems.....	74
Generics .....	74
R&D / Clinical Trials.....	75
Manufacturing.....	79
Distribution.....	80
Patent & Intellectual Property Issues.....	82
The Monitoring Period.....	84
Provisional vs. Final Standards.....	85
Compulsory Licensing.....	85
Marketing.....	86
Marketing Regulations.....	86
Marketing Practices .....	87
<b>Country: India.....</b>	<b>91</b>
Major Events.....	92
Healthcare System .....	93
Pharmaceutical Market .....	97
Market Profile and Structure.....	98
Market Performance and Forecasts.....	100

Regulatory.....	102
Approval Procedures.....	105
Biosimilar Regulations.....	107
Proposal to Restrict New Drug Approvals to Generic Names.....	108
Reports of Lax Regulatory Oversight.....	108
Pricing.....	108
Details of New Price Control System.....	109
Proposals for Patented Medicine Price Controls.....	111
Payment.....	112
Generics.....	113
R&D / Clinical Trials.....	114
Clinical Trial Regulations.....	114
Clinical Trial Environment.....	116
Manufacturing.....	118
Distribution.....	120
Patent & Intellectual Property Issues.....	121
Provisions of the Patent Law.....	123
Lack of Data Exclusivity.....	125
Recent Developments and Future Outlook.....	126
Marketing.....	127
Marketing Practices.....	128
<b>Country: Indonesia.....</b>	<b>131</b>
Major Events.....	132
Healthcare System.....	133
Health Infrastructure.....	134
Health Insurance.....	135
Universal Health System Status.....	136
Pharmaceutical Market.....	138

Market Profile .....	139
Regulatory Barriers and Market Access .....	142
Market Performance and Forecasts.....	143
Regulatory.....	144
Approval Procedures.....	145
Pricing.....	147
Payment.....	148
PT Askes Formulary (DPHO).....	149
Generics .....	150
R&D / Clinical Trials.....	151
Manufacturing.....	152
Distribution .....	153
Patent & Intellectual Property Issues.....	154
Compulsory Licensing.....	154
Marketing.....	155
<b>Country: Japan .....</b>	<b>158</b>
Healthcare System .....	159
Healthcare Infrastructure .....	161
Pharmaceutical Market .....	163
Market Profile and Structure.....	163
Market Performance and Forecasts.....	165
Forecasts .....	166
Regulatory.....	167
<a href="http://www.jpma.or.jp/english/parj/1203.html">http://www.jpma.or.jp/english/parj/1203.html</a> .....	167
Approval Procedures.....	168
Pricing.....	171
General Procedures .....	171
Adjustments to Calculated Price.....	172



Additional Factors in New Drug Pricing .....	173
Generic Pricing Procedures.....	174
Biennial Price Cuts .....	175
Price Maintenance System for Patented Drugs.....	175
Health Technology Assessment (HTA) Board under Consideration.....	176
Payment.....	176
Generics .....	177
Generic Companies.....	177
Generic Market .....	178
Generic Promotion Efforts.....	179
Biosimilars .....	180
R&D / Clinical Trials.....	181
Clinical Trial Environment .....	181
Clinical Trial Regulations.....	183
Manufacturing.....	184
Distribution.....	186
Patent & Intellectual Property Issues.....	187
Marketing.....	187
<b>Country: New Zealand .....</b>	<b>191</b>
Healthcare System .....	192
Pharmaceutical Market .....	195
Market Profile and Structure.....	196
PHARMAC.....	196
Market Performance and Forecasts.....	198
Regulatory.....	200
Approval Procedures.....	200
TGA/Medsafe Merger (ANZTPA) Status .....	201
Pricing.....	201

PHARMAC's Role in Hospital Purchases.....	203
Payment.....	204
Changes to the Exceptional Circumstances Scheme .....	204
Generics .....	205
R&D / Clinical Trials.....	205
Distribution .....	207
Trade .....	207
Patent & Intellectual Property Issues.....	208
Marketing.....	208
<b>Country: South Korea .....</b>	<b>211</b>
Healthcare System .....	212
Pharmaceutical Market .....	216
Market Profile and Structure.....	217
Innovation Incentives.....	218
Incrementally Modified Drugs.....	219
Market Performance and Forecasts.....	220
Regulatory.....	221
Approval Procedures.....	222
Pricing.....	223
Patented Drugs.....	224
April 2012 Pricing System for Non-patented Drugs.....	224
Original Drugs Losing Exclusivity .....	225
Generic Drugs .....	225
Ongoing Price Cutting Measures .....	225
Proposed Future Price Reforms .....	226
Payment.....	226
Hospital Purchasing and Payment .....	227
Generics .....	228

Biosimilars .....	228
R&D / Clinical Trials.....	229
Manufacturing.....	231
Distribution .....	232
Trade .....	233
Patent & Intellectual Property Issues.....	233
Korea-US Free Trade Agreement.....	234
<a href="http://www.ustr.gov/trade-agreements/free-trade-agreements/korus-fta/final-text">http://www.ustr.gov/trade-agreements/free-trade-agreements/korus-fta/final-text</a> .....	235
Marketing.....	235
<b>Country: Taiwan.....</b>	<b>238</b>
Healthcare System .....	239
Pharmaceutical Market .....	243
Market Profile and Structure.....	244
Market Performance and Forecasts.....	245
Regulatory.....	246
TFDA .....	247
Approval Procedures.....	247
Bridging Study Policies .....	248
Pricing.....	248
Patented Products.....	249
Health Technology Assessments (HTA) & Innovation Categories.....	249
Multi-Source Products .....	250
Price Volume Surveys.....	250
Impact of 2G NHI on Drug Pricing .....	251
Drug Expenditure Target (DET).....	251
Actual Transaction Pricing (ATP) .....	251
Payment.....	251
Generics .....	252

Biosimilars .....	253
R&D / Clinical Trials.....	253
Clinical Trials.....	253
IND Review Process .....	255
Manufacturing.....	255
Patent & Intellectual Property Issues.....	256
Marketing.....	257
<b>User License Agreement.....</b>	<b>260</b>

## Table of Figures

Figure 1 - Exchange Rates used in PharmaHandbook (2004-2012; Average Annual Value to US\$) .....	18
Figure 2 – Population and Economic Statistics .....	21
Figure 3 – General Healthcare Statistics.....	21
Figure 4 - Destination of Health Expenditures, FY 2009/10 .....	22
Figure 5 – Employed Medical Practitioners by Type and Practice Location.....	23
Figure 6 – Population Statistics .....	24
Figure 7 - Pharmaceutical Market Snapshot.....	24
Figure 8 - Structure of the Australian Prescription Drug Market .....	25
Figure 9 - FY 2010/11 PBS Activity by Category.....	27
Figure 10 - FY 2010/11 PBS Activity by ATC Level 2 Categories (Figures in 000; A\$).....	27
Figure 11 - Top 20 Pharma Companies by PBS Sales FY 2010/11 (A\$ and Rx Volume shown in thousands).....	43
Figure 12 - Pharmacy Reimbursement Rates - Standard PBS Drugs .....	44
Figure 13 - Pharmacy Reimbursement Rates – Highly Specialized Drugs.....	44
Figure 14 - Top 50 PBS Drugs by Cost to Government (A\$ and Rx Volume in thousands).....	49
Figure 15 – Population and Economic Statistics .....	53
Figure 16 – General Healthcare Statistics.....	53
Figure 17 – Health Insurance Coverage in China 2011 .....	56
Figure 18 – Demographic Profile .....	59
Figure 19 - Pharmaceutical Market Snapshot.....	59
Figure 20 - Chinese Cities by Tier.....	62
Figure 21 - Top 10 Pharmaceutical Companies (Q1 2012) .....	63
Figure 22 - Share of Market Value by Drug Type (Western Drugs: 2009-2011).....	63
Figure 23 - Procedures and Timeframe for Market Access in China .....	64
Figure 24 - Drug Approval Procedures & Timing.....	69
Figure 25 - Generics Share of Market Value and Volume Forecasts (2010-2015).....	74
Figure 26 - Clinical Trial Regulatory Approval Process .....	77
Figure 27 - Top 10 Pharmacy Chains 2011 .....	82
Figure 28 - Promotional Spending by Type 2011.....	88
Figure 29 – Promotional Spending by Company 2011 .....	88
Figure 30 – Population and Economic Statistics .....	92
Figure 31 – General Healthcare Statistics.....	92
Figure 32 - Health Insurance Coverage by Scheme (Millions of People) .....	95
Figure 33 – Demographic Profile .....	96
Figure 34 - Pharmaceutical Market Snapshot.....	97
Figure 35 - Pharmaceutical Markets by Location Type.....	98
Figure 36 – Sources of Pharmaceutical Market Growth 2007 to 2011 .....	99
Figure 37 - Retail and Hospital Sales and Share 2006-2011 .....	101
Figure 38 – Therapeutic Category Share of Market and Value Growth (Year-Ending Jun 2012 vs. Jun 2011).....	102
Figure 39 - Indian Regulatory System .....	103
Figure 40 - Responsibilities of Central and State Drug Regulators .....	104
Figure 41 - DPCO History.....	109
Figure 42 – Indian Clinical Trial Starts by Phase (Number and Share: 2006-2011) .....	118
Figure 43 – Top 50 Companies by sales in Indian Outpatient Market (MAT Mar 2012) .....	119
Figure 44 – Structure of Distribution Network.....	120
Figure 45 - Price Build-up in Distribution Channel.....	121
Figure 46 - Promotional Spending by Type 2011.....	128

Figure 47 – Top 10 Companies and Brands by Promotional Spending 2011 .....	129
Figure 48 – Population and Economic Statistics .....	132
Figure 49 – General Healthcare Statistics.....	133
Figure 50 – Trends in Public Health Centers (Puskesmas).....	134
Figure 51 – Distribution of Public and Private Hospitals (Aug 2012).....	135
Figure 52 – Demographic Profile .....	137
Figure 53 - Pharmaceutical Market Snapshot.....	138
Figure 54 - Sales and Share by Product Type 2007-2012 (Ex-manufacturer).....	139
Figure 55 - Leading Prescription and OTC Companies (2011) .....	140
Figure 56 - Leading Companies: Overall, Pharmacy, and Hospital Markets (2011).....	141
Figure 57 - Prescription and OTC Sales Forecasts (2012 to 2016).....	144
Figure 58 – Structure and Responsibilities within BPOM’s Directorate of Drug & Biological Product Evaluation	145
Figure 59 - Characteristics of the DPHO Formulary 2007 to 2012 .....	149
Figure 60 – Indonesian Clinical Trial Starts by Phase (Number and Share: 2006-2012).....	152
Figure 61 – Structure of Distribution Network.....	153
Figure 62 - Products covered by compulsory license decree (September 3, 2012) .....	155
Figure 63 – Population and Economic Statistics .....	159
Figure 64 – General Healthcare Statistics.....	159
Figure 65 - Types of Health Insurance Organizations .....	160
Figure 66 - Japanese Physicians by Specialty.....	161
Figure 67 – Demographic Structure.....	162
Figure 68 - Pharmaceutical Market Snapshot.....	163
Figure 69 – Prescription Drug Sales by Channel 2011 .....	164
Figure 70 - Sales of Ethical (Prescription) Drugs in Japan 2004-11; Local and US\$ Values.....	165
Figure 71 - 2011 Sales by Therapeutic Category.....	165
Figure 72 – Sales of Top 10 Products 2011 .....	166
Figure 73 - PMDA Drug Review Offices and Responsibilities .....	169
Figure 74 – Drug Pricing Process (Non-generics).....	171
Figure 75 – Leading Generic Companies 2010 .....	177
Figure 76 –Generic Penetration Rates 2005-11 .....	178
Figure 77 - Japanese Clinical Trial Starts by Phase (Number and Global Share: 2006-2011) .....	182
Figure 78 - Sales of Top 20 Companies 2011 (Distributor Level) .....	185
Figure 79 – Sales-Force Size (Number of MRs): Top 20 Companies 2010 .....	189
Figure 80 - Population and Economic Statistics .....	192
Figure 81 - General Healthcare Statistics .....	192
Figure 82 – Sources of Health Funds 2010.....	193
Figure 83 - Destinations of Funds FY 2010 .....	194
Figure 84 – Demographic Profile .....	195
Figure 85 - Pharmaceutical Market Snapshot.....	195
Figure 86 - PHARMAC Spending at Ex-Mfr Level by Category 2010 and 2011 Fiscal Years .....	198
Figure 87 - Top 20 Subsidized Products by Value and Prescription Volume FY 2011.....	199
Figure 88 – Population and Economic Statistics .....	212
Figure 89 – General Healthcare Statistics.....	212
Figure 90 - NHI Copayment Schedule 2012.....	213
Figure 91 - Number of Health Facilities by Type.....	214
Figure 92 – Demographic Profile .....	215
Figure 93 - Pharmaceutical Market Snapshot.....	216
Figure 94 – Summary of Pharmaceutical Market Reforms (2000 to 2012).....	217
Figure 95 - Sales of Prescription and OTC Drugs 2008-2011 (US Dollars).....	220
Figure 96 – 2011 Outpatient Prescription Drug Sales and Share by Therapeutic Category .....	221

Figure 97 - Korea Clinical Trial Starts by Phase (Number and Global Share: 2006-2011).....	230
Figure 98 – Leading Domestic Companies by Share of Value in the Outpatient Segment 2010-2011 .....	231
Figure 99 - Population and Economic Statistics .....	239
Figure 100 – General Healthcare Statistics.....	239
Figure 101 - Funding Flows for Personal Healthcare 2010 .....	241
Figure 102 – Health Spending by Destination 2010 .....	242
Figure 103 - Taiwan's Health Infrastructure 2012 .....	242
Figure 104 - Pharmaceutical Market Snapshot.....	243
Figure 105 - Pharmaceutical Copayment Rates 2012.....	252
Figure 106 - Number of Approved Clinical Trial Protocols and Sites by Phase (2004-2010) .....	254
Figure 107 - Taiwan Clinical Trial Starts by Phase (Number and Global Share: 2006-2011) .....	254